First-Line Sacituzumab Govitecan Plus Pembrolizumab in Metastatic NSCLC: PD-L1 TPS <50% and

INTRODUCTION: Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate previously studied in patients with pretreated metastatic non-small cell lung cancer (mNSCLC). Here, we report results of EVOKE-02 (NCT05186974), a global, open-label, multicohort phase 2 study of SG plus pembrolizumab as first-line treatment in patients with mNSCLC. METHODS: Adult patients without prior systemic mNSCLC treatment, and no actionable genomic alterations, received SG 10 mg/kg intravenously on days 1 and 8 plus pembrolizumab 200 mg intravenously on day 1 of 21-day cycles. The primary endpoint was objective response rate (ORR) per independent review committee, and secondary endpoints included progression-free survival (PFS) and safety. RESULTS: As of data cutoff (June 3, 2024), there were 30 patients with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS)

• Reck, M.
• Patel, J. D.
• Gray, J. E.
• Reguart, N.
• Cobo, M.
• Pradera, J. F.
• Felip, E.
• Cappuzzo, F.
• Garon, E. B.
• Neal, J. W.
• Mekan, S.
• Safavi, F.
• Fernando, N.
• Zavodovskaya, M.
• Jürgensmeier, J. M.
• Chisamore, M.
• Cho, B. C.